why choose us

First received: August 09, 2022

Clinical Trial: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Diffuse Large B-cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Trial Evaluating the Efficacy of Polatuzumab Vedotin With Rituximab, Gemcitabine, Dexamethasone, and Cisplatin (PV-RGDP) Chemotherapy for Relapsed or Refractory Diffuse Large B-cell Lymphom

Brief Summary: This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back or did not improve after the treatments (rrDLBCL).This combination has not been approved by the Food and Drug Administration (FDA) for the treatment of rrDLBCL.Salvage therapy (treatment after standard treatment failed) needs to be improved.Rituximab, gemcitabine,…

Read more